Navigation Links
Trapping prostate cancer cells to keep them from spreading provides hope
Date:3/10/2011

Tampa, Fla. (March 10, 2011) When prostate cancer stem cells (CSCs) were enclosed in self-assembling nanomaterials made of peptides (SAP), the SAP stopped cancer stem cell colony formation and also stopped the division of cancer cells in laboratory cultures (in vitro). According to the international team of researchers who built and tested the nano-sized traps and published their results in a recent issue of Cell Transplantation (20:1), which is freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , the cancer cells grew and multiplied after they were "liberated" from their SAP prisons.

In their article, the researchers suggested that CSCs may be the origin of prostate tumor metastasis, making them an "ideal target" for inhibiting disease metastasis. The group's previous work in building nanomaterials showed that by using SAPs they were able to control the proliferation, elongation and maturation of cells in vitro.

"In this study, we have shown that prostate CSCs can be placed into stasis for an extended period of time without causing them to differentiate," said study corresponding author Dr. Rutledge Ellis-Behnke of the Heidelberg University-based Nanomedicine Translational Think Tank. "If cells are prevented from migrating away from the treatment, they could be subjected to additional targeting."

For the researchers, the isolation of cancer cells with stem-like characteristics "provides solid evidence" that CSCs may exist within the tumor. Additionally, CSCs may account for some treatment failures when treatments are unable to successfully target cancer stem cells, which may be resistant to chemotherapy drugs. Too, CSCs have been found to be more invasive than non-CSCs. The authors speculated that by injecting the material directly into the tumor, it may be possible to stop the spread of metastatic cells.

The research team also suggested that trapping CSCs in the nanomaterial would allow for loading of the SAP with chemotherapy agents, thus offering an increased effectiveness of a localized treatment when targeted cancer cells were unable to 'escape' their chemical enemies. This approach for treating metastatic hormone refractory prostate cancer (HRPC) - a cancer for which all current therapies fail - may offer hope as a successful treatment.

"The goal of cancer therapy is to reduce the ability of cancer cells to divide and migrate," said Dr. Ellis-Behnke. "Accordingly, we have shown that SAP can completely inhibit a prostate CSC from self-renewal while preserving its viability and stem cell properties."

Their study concluded that SAP may be "an effective nanomaterial for inhibiting cancer progression and metastasis."

"The ability to sequester cancer stem cells in SAP to prevent the spread of a prostate cancer is a big step toward finding effective treatments for cancer," Shinn-Zong Lin, professor of neurosurgery at China University Medical Hospital, Taiwan and chair of the Pan Pacific Symposium on Stem Cell Research where this work was first presented. "It will be of considerable interest to se how this technology develops."


'/>"/>

Contact: David Eve
celltransplantation@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related medicine news :

1. New twist on potential malaria drug target acts by trapping parasites in cells
2. Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study
3. Newer Drug May Help Prevent Fracture in Men With Prostate Cancer
4. PSA velocity screening for prostate cancer may lead to unnecessary biopsies
5. Change in PSA level does not predict prostate cancer
6. PSA Screening for Prostate Cancer Dips in Large U.S. Health Network
7. HJF signs distribution agreement for antibody to evaluate prostate cancer
8. PSA Test Cut-off Could Signal Low-Risk Prostate Cancer
9. Research presented at 2011 GU Cancers Symposium highlights advances in treatment of prostate cancer
10. Could Hair Loss at 20 Signal Higher Prostate Cancer Risk?
11. Losing hair at 20 is linked to increased risk of prostate cancer in later life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... agency which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating ... lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone ...
(Date:1/19/2017)... , ... January 18, 2017 , ... The CHP suggests ... during a rain storm by slowing down and increasing the space between themselves and ... Los Angeles based car accident attorney Raymond R. Hassanlou notes that, rain or shine, ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... styled text designs that will simplify the editing process for all media productions," ... Basics is a package of 30 simplistically styled self-animating paragraphs designed for multi-lined ...
(Date:1/18/2017)... Austin, TX (PRWEB) , ... January 18, 2017 , ... ... million people opened a global discussion about the benefits of fidgeting to relieve stress ... Lyon and Jym Daniel. Their Think Ink Pen had just completed a successful ...
(Date:1/18/2017)... SAN JOSE, Calif, USA; and SHANGHAI, China – , ... ... January 18, 2017 -- Global public health organization NSF International ... V (pentavalent arsenic) to NSF/ANSI 53: Drinking Water Treatment Units ... treatment units. This certification verifies that MicroCeramics’ NanoNose Pitcher Filter ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017  EnteroMedics Inc. (NASDAQ: ETRM ... technology to treat obesity, metabolic diseases and other ... underwritten public offering of units for gross proceeds ... and commissions and offering expenses payable by EnteroMedics. ... A Units, priced at a public offering price ...
(Date:1/18/2017)...  Adaptive Sound Technologies, Inc. (ASTI), the leading supplier ... Hyatt Place Nashville/Downtown to deliver the best sleep experience ... machines in over two hundred of its guest rooms. ... of having a great stay is sleeping well," said ... Nashville/Downtown. "We,re pleased to be able to offer our ...
(Date:1/18/2017)... 18, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, announces dosing the ... a Phase 2 acne rosacea study. DMT210 is ... proinflammatory cytokines in the skin responsible for the ... This clinical trial, DMT210-003, is a ...
Breaking Medicine Technology: